Artificial intelligence in urological oncology: a scoping review of clinical applications
Academia Oncology · 16.11.2026 · 3 (4)
DOI: 10.20935/acadonco8608 ↗Kurz gefasst
Scoping Review in der Zeitschrift Academia Oncology, online erschienen am 16.11.2026. Verfasst von Gurpremjit Singh und 3 weiteren Autor:innen. Die Arbeit nennt 69 Literaturangaben.
Abstract (Originalsprache)
Artificial intelligence (AI) is being applied across urological oncology, yet few recent reviews have integrated its use across the major genitourinary malignancies in diagnosis, prognostication, and treatment planning. This scoping review mapped the contemporary literature on AI applications in prostate cancer, bladder cancer, and renal cell carcinoma using a Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR)-informed approach. PubMed/MEDLINE, Embase, Scopus, and the Cochrane Library were searched from database inception to 15 May 2026, and 35 studies were included. Across the included studies, AI showed strong performance in selected settings, including an area under the receiver operating characteristic curve (AUC) of 0.91 for clinically significant prostate cancer detection on MRI in the prostate imaging: cancer AI (PI-CAI) study, pooled accuracy of 92.3% for renal cell carcinoma histopathologic classification in pathology-focused meta-analytic data, and high reported AUCs in selected bladder cancer recurrence and cytology-related models. In general, multimodal approaches often performed well and in several studies outperformed single-modality models. However, most studies were retrospective, reporting standards were inconsistent, and prospective validation remained limited. In the wider literature, prostate cancer has received the most attention, with fewer robust studies in bladder and kidney cancers. Overall, AI holds considerable promise for improving precision oncology in urology, but broader clinical implementation will require standardized datasets, external and prospective validation, interpretable model design, and appropriate regulatory and ethical oversight.
Zitieren
APA
Singh, G., Rewari, H., Narayanaswamy, S., & Sabnani, S. (2026). Artificial intelligence in urological oncology: a scoping review of clinical applications. Academia Oncology, 3(4). https://doi.org/10.20935/acadonco8608
Vancouver
Singh G, Rewari H, Narayanaswamy S, Sabnani S. Artificial intelligence in urological oncology: a scoping review of clinical applications. Academia Oncology. 2026;3(4). doi:10.20935/acadonco8608
BibTeX
@article{Singh2026,
author = {Singh, Gurpremjit and Rewari, Harshit and Narayanaswamy, Supradeep and Sabnani, Smrati},
title = {Artificial intelligence in urological oncology: a scoping review of clinical applications},
journal = {Academia Oncology},
year = {2026},
volume = {3},
number = {4},
doi = {10.20935/acadonco8608}
}
EUVIMED